文献速递关节外科

假体周围感染治疗中改变手术入路不增加根治失败风险:多中心回顾性队列研究

Changing Surgical Approach During Periprosthetic Joint Infection Treatment Does Not Increase Risk of Eradication Failure: A Multicenter Retrospective Cohort Study.
PubMed 文献 · J Arthroplasty · 2026-04-20

该多中心回顾性队列研究纳入517例因假体周围感染(PJI)治疗的全髋关节置换术患者,其中431例有至少1年随访。结果显示23.8%的病例在PJI治疗中改变了手术入路,且入路改变与PJI治疗成功率(87.2%)及无菌性并发症无显著关联。结论认为改变入路在PJI治疗中是安全有效的,不增加感染或无菌性失败风险。

要点

  • PJI治疗中改变入路发生率为23.8%,多发生在首次手术干预时(19.9%)。
  • 前侧入路(62.1%)和外侧入路(51%)更常见入路改变,后侧入路仅0.7%(P<0.001)。
  • 入路改变与PJI治疗成功率(87.2%)及无菌性并发症无显著关联(P=0.73)。

核心结论

  • 在PJI治疗中,初次置换与PJI治疗采用一致或不同入路,结局相当。
  • 改变入路在PJI治疗中是安全有效的,不增加感染性或无菌性风险。

研究设计与样本

  • 伦理批准的多中心连续病例系列,纳入517例因PJI治疗的全髋关节置换术患者,平均年龄65岁(范围20-94),平均BMI 31(范围16.7-58.7),52.6%为女性。
  • 431例有至少1年随访(平均5年,范围1-17.2年)并纳入结局分析。
  • 原发入路以后侧为主(302例,58.4%),其次外侧(111例,21.5%)和前侧(104例,20.1%)。
  • 急性PJI占37%,其余为慢性感染;初始治疗包括清创、抗生素和假体保留(61.9%)、一期翻修(30.4%)和单期翻修(5.4%)。

主要发现

  • 改变入路发生在23.8%的病例中,多数发生在首次手术干预时(19.9%)。
  • 入路改变更常见于前侧入路(62.1%),其次外侧入路(51%)和后侧入路(0.7%)(P < 0.001)。
  • 入路改变更常见于一期翻修(36.3%)相比清创、抗生素和假体保留(17.2%)和单期翻修(10.7%)(P < 0.001)。
  • 未发现与入路改变相关的患者因素。
  • 末次随访时PJI治疗成功率为87.2%(376/431),与入路改变无关联(P = 0.73)。

关键数值与推荐

  • PJI治疗成功定义为Musculoskeletal Infection Society(MSIS)1至2级。
  • 无菌性并发症包括脱位、骨折和无菌性松动。

临床怎么用

  • 骨科医生在PJI治疗中可依据临床需要改变手术入路,无需担心增加根治失败或无菌性并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hip approach discordance in aseptic revision total hip arthroplasty is not associated with increased dislocation or rerevision risk. Whether the same holds true for the treatment of periprosthetic joint infection (PJI) is unknown. This study reported the rate of hip approach discordance during PJI treatment, identified associated factors, and tested possible associations with outcomes (septic and aseptic failures). METHODS: This is an ethics-approved, multicenter, consecutive case series of 517 primary total hip arthroplasties (mean age 65 years [range, 20 to 94], mean body mass index 31 [range, 16.7 to 58.7]), and 52.6% women treated for PJI. Of these, 431 had minimum 1-year follow-up (mean five years [range, one to 17.2]) and were included in the outcome analyses. Most index approaches were posterior (posterior approach: 302, 58.4%), followed by lateral (lateral approach: 111, 21.5%) and anterior (anterior approach: 104, 20.1%). Acute PJI accounted for 37% of cases, with the remaining cases representing chronic infections. Initial treatment across the entire cohort included debridement, antibiotics, and implant retention (61.9%), first-stage revision (30.4%), and single-stage revision (5.4%), reflecting management of both acute and chronic PJI. Outcomes of interest included PJI treatment success (Musculoskeletal Infection Society tiers 1 to 2) and aseptic complications (dislocation, fracture, and aseptic loosening). RESULTS: Change of approach occurred in 23.8% of cases, mostly occurring at the first surgical intervention (19.9%). Approach discordance was more common with anterior approach (62.1%), followed by lateral approach (51%) and posterior approach (0.7%) (P < 0.001), and with first-stage revisions (36.3%) compared to debridement, antibiotics, and implant retention (17.2%) and single-stage (10.7%) revisions (P < 0.001). There were no patient factors that were associated with approach discordance. Success of PJI treatment by the latest follow-up was 87.2% (376 of 431) and not associated with approach change (P = 0.73). Aseptic complications were seen in 4.4% of cases, with dislocation being most common (2.6%). There was no difference in overall complication or dislocation rates when the approach was changed (P = 0.33 to 0.73). CONCLUSIONS: Comparable outcomes are seen in PJI treatment with concordant and discordant approaches between primary and PJI treatment. These data provide reassurance to surgeons that the change of approach is safe and efficacious in PJI treatment without increased septic or aseptic risks.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Schmidt-Braekling T, Khury F, Aggarwal V, et al. Changing Surgical Approach During Periprosthetic Joint Infection Treatment Does Not Increase Risk of Eradication Failure: A Multicenter Retrospective Cohort Study. J Arthroplasty. 2026. PMID: 42019777. doi:10.1016/j.arth.2026.04.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。